Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Change in Accured Expenses (2016 - 2021)

GT Biopharma (GTBP) has disclosed Change in Accured Expenses for 12 consecutive years, with $152000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Change in Accured Expenses fell 91.72% to $152000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $689000.0, a 77.03% decrease, with the full-year FY2025 number at -$1.3 million, down 238.42% from a year prior.
  • Change in Accured Expenses was $152000.0 for Q4 2021 at GT Biopharma, up from -$152000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.1 million in Q4 2019 to a low of -$1.9 million in Q4 2017.
  • A 5-year average of $371117.6 and a median of $598000.0 in 2017 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 558.54% in 2017, then soared 253.0% in 2019.
  • GT Biopharma's Change in Accured Expenses stood at -$1.9 million in 2017, then skyrocketed by 71.6% to -$534000.0 in 2018, then skyrocketed by 484.46% to $2.1 million in 2019, then dropped by 10.62% to $1.8 million in 2020, then plummeted by 91.72% to $152000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Change in Accured Expenses are $152000.0 (Q4 2021), -$152000.0 (Q3 2021), and -$7000.0 (Q2 2021).